The Supreme Court handed down a major ruling in a long-running legal battle over whether the weedkiller Roundup causes cancer, a decision with broad implications for thousands of pending lawsuits and for how federal law interacts with state product liability claims.
According to STAT News, the court ruled in a case involving Roundup, the widely used herbicide whose active ingredient is glyphosate. The case centered on whether federal pesticide law prevents plaintiffs from bringing state court claims that the product's label failed to adequately warn users about cancer risk.
Roundup is made by Bayer, which acquired the product when it purchased Monsanto in 2018. The company inherited massive legal liability along with the acquisition. Tens of thousands of plaintiffs have claimed that exposure to glyphosate caused them to develop non-Hodgkin's lymphoma, a type of blood cancer.
The central legal question before the court involved federal preemption, specifically whether the Federal Insecticide, Fungicide, and Rodenticide Act, the law that governs pesticide labeling in the United States, blocks state law failure-to-warn claims. The Environmental Protection Agency has determined that glyphosate is not likely to be carcinogenic to humans, a conclusion that differs from a 2015 assessment by the World Health Organization's cancer research arm, which classified it as a probable human carcinogen.
Bayer has argued that because the EPA has reviewed and approved the Roundup label, state courts cannot require the company to carry additional cancer warnings. Plaintiffs have argued that federal law does not fully displace state rights to hold companies accountable for inadequate safety warnings.
The Supreme Court's ruling in favor of Bayer's position limits the legal avenues available to people who claim the herbicide caused their cancer. The decision is expected to affect not only current cases but also the legal strategy for future plaintiffs.
The ruling does not settle the underlying scientific debate about whether glyphosate causes cancer. That question continues to be contested among researchers, regulatory agencies, and public health advocates. What the decision does determine is a legal boundary, establishing how much room state courts have to second-guess a federal agency's determination about a product label.
Bayer has faced billions of dollars in jury verdicts in lower courts, though many of those verdicts have been appealed or reduced. The company has been trying for years to reach a global settlement that would resolve the litigation, but those efforts have faced obstacles. The Supreme Court decision may shift the legal landscape significantly in Bayer's favor going forward.
